Evaluation of the Efficacy and Safety of the Application of BeGraft Peripheral Stent Graft System

Inclusion Criteria: * Aged ≥18 years old, no restrictions in terms of male or female; * Participating in the trial voluntarily, and having signed the informed consent form; * TASC class A, B, C or D lesions of the common iliac artery and/or external iliac artery; * Primary iliac atherosclerotic stenosis and/or occlusive lesions; * Total length of lesions on the affected side ≤100 mm. Exclusion Criteria: * Expected survival period \<12 months; * Pregnant women or those unable to take effective contraceptive measures during the trial; * Aneurysms present close to the target lesion; * Acute or subacute thrombosis within the target vessel; * Previously unobstructed internal iliac artery being blocked (diameter stenosis \<70%) by the stented region; * Total occlusive lesions, with the guidewire being unable to return the true lumen in the iliac artery; * Severe calcification at the target lesion, with the catheter being unable to pass; * Allergic to cobalt-chromium alloy (L605), ePFTE coating material, carbon coating, contrast agent, antiplatelet agents, anticoagulant drugs or presenting with contraindications; * Total occlusion of the superficial femoral artery and deep femoral artery, with there being no outflow tract; * Suffering from extensive diffuse disease at the distal end, resulting in poor blood flow in the outflow tract following stent placement; * A history of coagulation disorders; * The subject's mental state making it impossible for them to comprehend the nature, extent and possible consequences of the trial, or having a language barrier making it difficult for the subject to give their informed consent; * Poor cooperation or potentially poor compliance with the protocol which may cause deviations during the trial.